Stock Track | Baxter Soars 8.24% on Strong Q4 Results, Robust 2025 Outlook

Stock Track

Feb 20, 2025

Baxter International Inc.'s (NYSE: BAX) stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.

The medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.

Baxter's strong performance has boosted investor confidence, as the company provided an optimistic outlook for 2025. The company expects sales growth from continuing operations of 5% to 6% on a reported basis, and 4% to 5% on an operational basis. Additionally, Baxter projected adjusted earnings from continuing operations, before special items, to range between $2.45 and $2.55 per diluted share, exceeding the consensus estimate of $2.47.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142837772"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142837772\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142837772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142837772","market":"hk","top_or_hot":-1,"title":"Stock Track | Baxter Soars 8.24% on Strong Q4 Results, Robust 2025 Outlook","media":"Stock Track","content":"<p>Baxter International Inc.'s (NYSE: BAX) stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.</p>\n\n<p>The medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.</p>\n\n<p>Baxter's strong performance has boosted investor confidence, as the company provided an optimistic outlook for 2025. The company expects sales growth from continuing operations of 5% to 6% on a reported basis, and 4% to 5% on an operational basis. Additionally, Baxter projected adjusted earnings from continuing operations, before special items, to range between $2.45 and $2.55 per diluted share, exceeding the consensus estimate of $2.47.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Baxter Soars 8.24% on Strong Q4 Results, Robust 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Baxter Soars 8.24% on Strong Q4 Results, Robust 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-20 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Baxter International Inc.'s (NYSE: BAX) stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.</p>\n\n<p>The medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.</p>\n\n<p>Baxter's strong performance has boosted investor confidence, as the company provided an optimistic outlook for 2025. The company expects sales growth from continuing operations of 5% to 6% on a reported basis, and 4% to 5% on an operational basis. Additionally, Baxter projected adjusted earnings from continuing operations, before special items, to range between $2.45 and $2.55 per diluted share, exceeding the consensus estimate of $2.47.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAX","symbol_name":"百特国际","start_time":0,"source_url":"","article_id":"1142837772","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142837772","pubTimestamp":1740063684,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Baxter International Inc.'s  stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.The medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.Baxter's","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAX":"百特国际"},"translate_title":"股票追踪百特(Baxter)因强劲的第四季度业绩和强劲的2025年前景而飙升8.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAX":1},"content_text":"Baxter International Inc.'s (NYSE: BAX) stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.\nThe medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.\nBaxter's strong performance has boosted investor confidence, as the company provided an optimistic outlook for 2025. The company expects sales growth from continuing operations of 5% to 6% on a reported basis, and 4% to 5% on an operational basis. Additionally, Baxter projected adjusted earnings from continuing operations, before special items, to range between $2.45 and $2.55 per diluted share, exceeding the consensus estimate of $2.47.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}